Unión Europea - español - EMA (European Medicines Agency)

mylan pharmaceuticals limited - anagrelide clorhidrato de - trombocitemia, esencial - agentes antineoplásicos - anagrelide está indicado para la reducción de los elevados recuentos de plaquetas en riesgo trombocitemia esencial (et) de los pacientes que son intolerantes a su terapia actual o cuyos elevados recuentos de plaquetas no son reducidos a un nivel aceptable por su terapia actual. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - caspofungina acetato - polvo para concentrado para soluciÓn para perfusiÓn - 50 mg - caspofungina acetato 50 mg - caspofungina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - caspofungina acetato - polvo para concentrado para soluciÓn para perfusiÓn - 70 mg - caspofungina acetato 70 mg - caspofungina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - tigeciclina - polvo para soluciÓn para perfusiÓn - 50 mg - tigeciclina 50 mg - tigeciclina

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - acetato de abiraterona - neoplasmas prostáticos - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - fumarato de dimetilo - la esclerosis múltiple remitente-recurrente - inmunosupresores - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

mylan pharma gmbh suiza - clozapina básica (cas5786-21-0) 100,00 mg - comprimidos - cada comprimido contiene: clozapina básica (cas5786-21-0) 100,00 mg

Unión Europea - español - EMA (European Medicines Agency)

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - agentes antineoplásicos - tratamiento del cáncer de mama, formas especiales de cáncer de pulmón (cáncer de pulmón de células no pequeñas), cáncer de próstata, cáncer gástrico o cáncer de cabeza y cuello.